Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  More, Sandeep Vasant ^a   Kumar, Hemant ^a   Kim, In Su ^a   Song, Soo Yeol ^a   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; COMPLEMENT;

ASTROCYTE; CD4+ T LYMPHOCYTE; CELL MIGRATION; COMPLEMENT SYSTEM; HUMAN; LEUKOCYTE FUNCTION; MACROPHAGE; MICROGLIA; MONOCYTE; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARENCHYMA; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; BRAIN; CYTOLOGY; DISEASE COURSE; GENETICS; INFLAMMATION; INNATE IMMUNITY; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ASTROCYTES; BRAIN; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICROGLIA; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84880172298     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/952375     Document Type: Review

References (147)

1. Nolan Y. M., Sullivan A. M., Toulouse A., Parkinson's disease in the nuclear age of neuroinflammation. Trends in Molecular Medicine 2013 19 3 187 196
2. Moore D. J., West A. B., Dawson V. L., Dawson T. M., Molecular pathophysiology of Parkinson's disease. Annual Review of Neuroscience 2005 28 57 87 2-s2.0-20744435383 10.1146/annurev.neuro.28.061604.135718 (Pubitemid 41098899)
3. McGeer P. L., McGeer E. G., Glial reactions in Parkinson's disease. Movement Disorders 2008 23 4 474 483 2-s2.0-47349104402 10.1002/mds.21751
4. Schapira A. H. V., Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Movement Disorders 1994 9 2 125 138 2-s2.0-0028274216 (Pubitemid 24092327)
5. Ben-Shachar D., Zuk R., Glinka Y., Dopamine neurotoxicity: inhibition of mitochondrial respiration. Journal of Neurochemistry 1995 64 2 718 723 2-s2.0-0028813395
6. Rosenberg R. N., Mitochondrial therapy for Parkinson disease. Archives of Neurology 2002 59 10 1523 2-s2.0-0036791769 10.1001/archneur.59.10.1523
7. Lee J., Tran T., Tansey M. G., Neuroinflammation in Parkinson's disease. Journal of Neuroimmune Pharmacology 2009 4 4 419 429 2-s2.0-70449517404 10.1007/s11481-009-9176-0
8. McGeer P. L., Yasojima K., McGeer E. G., Inflammation in Parkinson's disease. Advances in Neurology 2001 86 83 89 2-s2.0-0035236738
9. Whitton P. S., Inflammation as a causative factor in the aetiology of Parkinson's disease. British Journal of Pharmacology 2007 150 8 963 976 2-s2.0-34247366072 10.1038/sj.bjp.0707167 (Pubitemid 46628616)
10. Ransohoff R. M., Perry V. H., Microglial physiology: unique stimuli, specialized responses. Annual Review of Immunology 2009 27 119 145 2-s2.0-67650966680 10.1146/annurev.immunol.021908.132528
11. Banati R. B., Daniel S. E., Blunt S. B., Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Movement Disorders 1998 13 2 221 227 2-s2.0-0031930771 10.1002/mds.870130205 (Pubitemid 28127795)
12. Damier P., Hirsch E. C., Zhang P., Agid Y., Javoy-Agid F., Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993 52 1 1 6 2-s2.0-0027434596 10.1016/0306-4522(93)90175-F (Pubitemid 23026600)
13. McGeer P. L., Itagaki S., Akiyama H., McGeer E. G., Rate of cell death in parkinsonism indicates active neuropathological process. Annals of Neurology 1988 24 4 574 576 2-s2.0-0023740773
14. Tansey M. G., McCoy M. K., Frank-Cannon T. C., Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Experimental Neurology 2007 208 1 1 25 2-s2.0-35348966882 10.1016/j.expneurol.2007.07.004 (Pubitemid 47603240)
15. Cross A. K., Woodroofe M. N., Immunoregulation of microglial functional properties. Microscopy Research and Technique 2001 54 1 10 17 2-s2.0-0035399774 10.1002/jemt.1115 (Pubitemid 32537329)
16. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debré P., Agid Y., Dugas B., Hirsch E. C., Fc ε RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor- α in glial cells. The Journal of Neuroscience 1999 19 9 3440 3447 2-s2.0-0033121299 (Pubitemid 29203124)
17. Nagatsu T., Mogi M., Ichinose H., Togari A., Cytokines in Parkinson's disease. Journal of Neural Transmission, Supplement 2000 58 143 151 2-s2.0-0033694060
18. Hirsch E. C., Hunot S., Hartmann A., Neuroinflammatory processes in Parkinson's disease. Parkinsonism and Related Disorders 2005 11 supplement 1 S9 S15 2-s2.0-18844374851 10.1016/j.parkreldis.2004.10.013 (Pubitemid 40693572)
19. Hirsch E. C., Vyas S., Hunot S., Neuroinflammation in Parkinson's disease. Parkinsonism and Related Disorders 2012 18 supplement 1 S210 S212 2-s2.0-84858667311
20. Lee Mosley R., Benner E. J., Kadiu I., Thomas M., Boska M. D., Hasan K., Laurie C., Gendelman H. E., Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. Clinical Neuroscience Research 2006 6 5 261 281 2-s2.0-33845211714 10.1016/j.cnr.2006.09.006 (Pubitemid 44849177)
21. Stone D. K., Reynolds A. D., Mosley R. L., Gendelman H. E., Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxidants and Redox Signaling 2009 11 9 2151 2166 2-s2.0-68249145501 10.1089/ars.2009.2460
22. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. The Journal of Clinical Investigation 2009 119 1 182 192 2-s2.0-58849107919 10.1172/JCI36470
23. Rezai-Zadeh K., Gate D., Town T., CNS infiltration of peripheral immune cells: D-day for neurodegenerative disease? Journal of Neuroimmune Pharmacology 2009 4 4 462 475 2-s2.0-70449534695 10.1007/s11481-009-9166-2
24. Teismann P., Schulz J. B., Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell and Tissue Research 2004 318 1 149 161 2-s2.0-5444228135 10.1007/s00441-004-0944-0 (Pubitemid 39362635)
25. Perry V. H., Innate inflammation in Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2012 2 9 a009373
26. Nimmerjahn A., Kirchhoff F., Helmchen F., Neuroscience: resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005 308 5726 1314 1318 2-s2.0-19744380563 10.1126/science.1110647 (Pubitemid 40746128)
27. Kreutzberg G. W., Microglia: a sensor for pathological events in the CNS. Trends in Neurosciences 1996 19 8 312 318 2-s2.0-0030222037 10.1016/0166-2236(96)10049-7 (Pubitemid 26349059)
28. Hunot S., Hirsch E. C., Isacson I., Olanow O., Rascol R., Schapira S., Beal B., Jenner J., Neuroinflammatory processes in Parkinson's disease. Annals of Neurology 2003 53 supplement 3 S49 S60 2-s2.0-0037378023 10.1002/ana.10481 (Pubitemid 36368562)
29. McGeer P. L., McGeer E., Innate immunity, local inflammation, and degenerative disease. Science of Aging Knowledge Environment 2002 2002 29, article re3 2-s2.0-4344701954
30. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006 21 2 404 412 2-s2.0-30744472146 10.1016/j.nbd.2005.08.002 (Pubitemid 43099863)
31. Gordon S., Taylor P. R., Monocyte and macrophage heterogeneity. Nature Reviews Immunology 2005 5 12 953 964 2-s2.0-28544446111 10.1038/nri1733 (Pubitemid 41746764)
32. Gordon S., Martinez F. O., Alternative activation of macrophages: mechanism and functions. Immunity 2010 32 5 593 604 2-s2.0-77953268611 10.1016/j.immuni.2010.05.007
33. Mosser D. M., Edwards J. P., Exploring the full spectrum of macrophage activation. Nature Reviews Immunology 2008 8 12 958 969 2-s2.0-56749174940 10.1038/nri2448
34. Lawson L. J., Perry V. H., Dri P., Gordon S., Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990 39 1 151 170 2-s2.0-0025220976 10.1016/0306-4522(90)90229-W
35. Kim W., Mohney R. P., Wilson B., Jeohn G., Liu B., Hong J., Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. The Journal of Neuroscience 2000 20 16 6309 6316 2-s2.0-0034663061 (Pubitemid 30658427)
36. Qian L., Flood P. M., Hong J., Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. Journal of Neural Transmission 2010 117 8 971 979 2-s2.0-77956958953 10.1007/s00702-010-0428-1
37. Walsh S., Finn D. P., Dowd E., Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011 175 251 261 2-s2.0-78951488151 10.1016/j.neuroscience.2010.12.005
38. McGeer P. L., Schwab C., Parent A., Doudet D., Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Annals of Neurology 2003 54 5 599 604 2-s2.0-0242384667 10.1002/ana.10728 (Pubitemid 37346066)
39. Sugama S., Yang L., Cho B. P., DeGiorgio L. A., Lorenzl S., Albers D. S., Beal M. F., Volpe B. T., Joh T. H., Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Research 2003 964 2 288 294 2-s2.0-0037469952 10.1016/S0006-8993(02)04085-4 (Pubitemid 36165153)
40. Möller T., Hanisch U., Ransom B. R., Thrombin-induced activation of cultured rodent microglia. Journal of Neurochemistry 2000 75 4 1539 1547 2-s2.0-0033822556 10.1046/j.1471-4159.2000.0751539.x
41. Tsirka S. E., Clinical implications of the involvement of tPA in neuronal cell death. Journal of Molecular Medicine 1997 75 5 341 347 2-s2.0-0030986802 10.1007/s001090050119 (Pubitemid 27247965)
42. Block M. L., Hong J., Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Progress in Neurobiology 2005 76 2 77 98 2-s2.0-24144453087 10.1016/j.pneurobio.2005.06.004 (Pubitemid 41242883)
43. Ko H. M., Koppula S., Kim B., Kim I. S., Hwang B. Y., Suk K., Park E. J., Choi D., Inflexin attenuates proinflammatory responses and nuclear factor- Κ B activation in LPS-treated microglia. European Journal of Pharmacology 2010 633 1-3 98 106 2-s2.0-77950027876 10.1016/j.ejphar.2010.02.011
44. Chow Y., Lee K., Vidyadaran S., Lajis N. H., Akhtar M. N., Israf D. A., Syahida A., Cardamonin from Alpinia rafflesiana inhibits inflammatory responses in IFN- γ /LPS-stimulated BV2 microglia via NF- B signalling pathway. International Immunopharmacology 2012 12 4 657 665 2-s2.0-84859161913 10.1016/j.intimp.2012.01.009
45. Herrera A. J., Castaño A., Venero J. L., Cano J., Machado A., The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiology of Disease 2000 7 4 429 447 2-s2.0-0033835748 10.1006/nbdi.2000.0289
46. Biber K., Neumann H., Inoue K., Boddeke H. W. G. M., Neuronal "On" and "Off" signals control microglia. Trends in Neurosciences 2007 30 11 596 602 2-s2.0-35748939409 10.1016/j.tins.2007.08.007 (Pubitemid 350051426)
47. Kim Y. S., Joh T. H., Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine 2006 38 4 333 347 2-s2.0-33748447845
48. Hoek R. H., Ruuls S. R., Murphy C. A., Wright G. J., Goddard R., Zurawski S. M., Blom B., Homola M. E., Streit W. J., Brown M. H., Barclay A. N., Sedgwick J. D., Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000 290 5497 1768 1771 2-s2.0-17744388105 10.1126/science.290.5497.1768 (Pubitemid 32004808)
49. Wright G. J., Jones M., Puklavec M. J., Brown M. H., Barclay A. N., The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 2001 102 2 173 179 2-s2.0-0035103077 10.1046/j.1365-2567.2001.01163.x (Pubitemid 32217509)
50. Neumann H., Control of glial immune function by neurons. Glia 2001 36 2 191 199 2-s2.0-0035149257 10.1002/glia.1108 (Pubitemid 33055907)
51. Barclay A. N., Brown M. H., The SIRP family of receptors and immune regulation. Nature Reviews Immunology 2006 6 6 457 464 2-s2.0-33745712879 10.1038/nri1859
52. Cardona A. E., Pioro E. P., Sasse M. E., Kostenko V., Cardona S. M., Dijkstra I. M., Huang D., Kidd G., Dombrowski S., Dutta R., Lee J., Cook D. N., Jung S., Lira S. A., Littman D. R., Ransohoff R. M., Control of microglial neurotoxicity by the fractalkine receptor. Nature Neuroscience 2006 9 7 917 924 2-s2.0-33745573660 10.1038/nn1715 (Pubitemid 43980506)
53. Limatola C., Lauro C., Catalano M., Ciotti M. T., Bertollini C., Di Angelantonio S., Ragozzino D., Eusebi F., Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. Journal of Neuroimmunology 2005 166 1-2 19 28 2-s2.0-23044464868 10.1016/j.jneuroim.2005. 03.023 (Pubitemid 41074653)
54. de Jong E. K., Dijkstra I. M., Hensens M., Brouwer N., van Amerongen M., Liem R. S. B., Boddeke H. W. G. M., Biber K., Vesicle-mediated transport and release of CCL21 in endangered neurons: a possible explanation for microglia activation remote from a primary lesion. The Journal of Neuroscience 2005 25 33 7548 7557 2-s2.0-23844452985 10.1523/JNEUROSCI.1019-05.2005 (Pubitemid 41170612)
55. + T-cell recruitment and control of West Nile virus encephalitis. Journal of Virology 2005 79 17 11457 11466 2-s2.0-23844435550 10.1128/JVI.79.17.11457-11466.2005 (Pubitemid 41170686)
56. Taylor D. L., Diemel L. T., Pocock J. M., Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. The Journal of Neuroscience 2003 23 6 2150 2160 2-s2.0-0037444442 (Pubitemid 36368903)
57. Wang X., Arcuino G., Takano T., Lin J., Peng W. G., Wan P., Li P., Xu Q., Liu Q. S., Goldman S. A., Nedergaard M., P2X7 receptor inhibition improves recovery after spinal cord injury. Nature Medicine 2004 10 8 821 827 2-s2.0-4043079197 10.1038/nm1082 (Pubitemid 39070855)
58. Koizumi S., Shigemoto-Mogami Y., Nasu-Tada K., Shinozaki Y., Ohsawa K., Tsuda M., Joshi B. V., Jacobson K. A., Kohsaka S., Inoue K., UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 2007 446 7139 1091 1095 2-s2.0-34247637676 10.1038/nature05704 (Pubitemid 46676051)
59. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F., Joh T. H., Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. The Journal of Neuroscience 2005 25 14 3701 3711 2-s2.0-17044432238 10.1523/JNEUROSCI.4346- 04.2005
60. Yoon S. K., Dong H. C., Block M. L., Lorenzl S., Yang L., Youn J. K., Sugama S., Byung P. C., Hwang O., Browne S. E., Soo Y. K., Hong J., Beal M. F., Joh T. H., A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. The FASEB Journal 2007 21 1 179 187 2-s2.0-33845977715 10.1096/fj.06-5865com (Pubitemid 46052555)
61. Chang R. C. C., Hudson P., Wilson B., Haddon L., Hong J., Influence of neurons on lipopolysaccharide-stimulated production of nitric oxide and tumor necrosis factor- α by cultured glia. Brain Research 2000 853 2 236 244 2-s2.0-0033987949 10.1016/S0006-8993(99)02255-6 (Pubitemid 30035223)
62. Zecca L., Zucca F. A., Wilms H., Sulzer D., Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends in Neurosciences 2003 26 11 578 580 2-s2.0-0242285663 10.1016/j.tins.2003.08.009 (Pubitemid 37338363)
63. Calabrese V. P., Hadfield M. G., Parkinsonism and extraocular motor abnormalities with unusual neuropathological findings. Movement Disorders 1991 6 3 257 260 2-s2.0-0025914065
64. Shamoto-Nagai M., Maruyama W., Akao Y., Osawa T., Tribl F., Gerlach M., Zucca F. A., Zecca L., Riederer P., Naoi M., Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. Journal of Neural Transmission 2004 111 10-11 1253 1265 2-s2.0-7944227205 10.1007/s00702-004-0211-2 (Pubitemid 39468389)
65. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., Lucius R., Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. The FASEB Journal 2003 17 3 500 502 2-s2.0-0037366093
66. Ciesielski-Treska J., Ulrich G., Taupenot L., Chasserot-Golaz S., Corti A., Aunis D., Bader M., Chromogranin a induces a neurotoxic phenotype in brain microglial cells. The Journal of Biological Chemistry 1998 273 23 14339 14346 2-s2.0-0032486395 10.1074/jbc.273.23.14339 (Pubitemid 28319150)
67. Taupenot L., Ciesielski-Treska J., Ulrich G., Chasserot-Golaz S., Aunis D., Bader M.-F., Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells. Neuroscience 1996 72 2 377 389 2-s2.0-0029964265 10.1016/0306-4522(96)83172-1 (Pubitemid 26111203)
68. Yasuhara O., Kawamata T., Aimi Y., McGeer E. G., McGeer P. L., Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. Neuroscience Letters 1994 170 1 13 16 2-s2.0-0028331317 10.1016/0304-3940(94)90227-5 (Pubitemid 24117275)
69. Wu X., Block M. L., Zhang W., Qin L., Wilson B., Zhang W., Veronesi B., Hong J., The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxidants and Redox Signaling 2005 7 5-6 654 661 2-s2.0-16344386871 10.1089/ars.2005.7.654 (Pubitemid 40563204)
70. Block M. L., Zecca L., Hong J., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038 (Pubitemid 46011999)
71. Choi D. K., Koppula S., Choi M., Suk K., Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target. Expert Opinion on Therapeutic Patents 2010 20 11 1531 1546 2-s2.0-77958453625 10.1517/13543776.2010.525220
72. Qian L., Block M. L., Wei S., Lin C., Reece J., Pang H., Wilson B., Hong J., Flood P. M., Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase. Journal of Pharmacology and Experimental Therapeutics 2006 319 1 44 52 2-s2.0-33749036329 10.1124/jpet.106.106351 (Pubitemid 44455109)
73. Zhang W., Dallas S., Zhang D., Guo J., Pang H., Wilson B., Miller D. S., Chen B., Zhang W., Mcgeer P. L., Hong J., Zhang J., Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007 55 11 1178 1188 2-s2.0-34547637625 10.1002/glia.20532 (Pubitemid 47204209)
74. Dawson V. L., Dawson T. M., Bartley D. A., Uhl G. R., Snyder S. H., Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. The Journal of Neuroscience 1993 13 6 2651 2661 2-s2.0-0027178135 (Pubitemid 23151779)
75. Knott C., Stern G., Wilkin G. P., Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Molecular and Cellular Neuroscience 2000 16 6 724 739 2-s2.0-0034520395 10.1006/mcne.2000.0914 (Pubitemid 32062060)
76. Koppula S., Kumar H., Kim I. S., Choi D. K., Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease. Mediators of Inflammation 2012 2012 16 823902 10.1155/2012/823902
77. Teismann P., COX-2 in the neurodegenerative process of Parkinson's disease. Biofactors 2012 38 6 395 397
78. Tsai S., Chao C., Yin M., Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. European Journal of Pharmacology 2011 670 2-3 441 447 2-s2.0-80755153266 10.1016/j.ejphar.2011.09.171
79. Przybylkowski A., Kurkowska-Jastrzebska I., Joniec I., Ciesielska A., Czlonkowska A., Czlonkowski A., Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration to mouse. Brain Research 2004 1019 1-2 144 151 2-s2.0-4043167628 10.1016/j.brainres.2004.05.095 (Pubitemid 39078620)
80. Teismann P., Tieu K., Choi D., Wu D., Naini A., Hunot S., Vila M., Jackson-Lewis V., Przedborski S., Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2003 100 9 5473 5478 2-s2.0-0038641723 10.1073/pnas.0837397100 (Pubitemid 36542729)
81. +-induced COX-2 activation and subsequent dopaminergic neurodegeneration. The FASEB Journal 2005 19 9 1134 1136 2-s2.0-21744433163 10.1096/fj.04-2457fje (Pubitemid 40946442)
82. Teismann P., Vila M., Choi D.-K., Tieu K., Wu D. C., Jackson-Lewis V., Przedborski S., COX-2 and neurodegeneration in Parkinson's disease. Annals of the New York Academy of Sciences 2003 991 272 277 2-s2.0-0038389514 (Pubitemid 36793820)
83. Sánchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A., Isacson O., Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. Journal of Neuroinflammation 2004 1 1, article 6 2-s2.0-4344645719 10.1186/1742-2094-1-6 (Pubitemid 39130328)
84. Teismann P., Ferger B., Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001 39 2 167 174 (Pubitemid 32104022)
85. Feng Z., Li D., Fung P. C. W., Pei Z., Ramsden D. B., Ho S., COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. NeuroReport 2003 14 15 1927 1929 2-s2.0-0642339281 10.1097/00001756-200310270- 00009 (Pubitemid 38339762)
86. Zhang W., Wang T., Pei Z., Miller D. S., Wu X., Block M. L., Wilson B., Zhang W., Zhou Y., Hong J., Zhang J., Aggregated α -synuclein activates microglia: a process leading to disease progression in Parkinson's disease. The FASEB Journal 2005 19 6 533 542 2-s2.0-20144389524 10.1096/fj.04-2751com (Pubitemid 40471244)
87. Koharudin L. M. I., Liu H., Di Maio R., Kodali R. B., Graham S. H., Gronenborn A. M., Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proceedings of the National Academy of Sciences of the United States of America 2010 107 15 6835 6840 2-s2.0-77951069130 10.1073/pnas.1002295107
88. De Lella Ezcurra A. L., Chertoff M., Ferrari C., Graciarena M., Pitossi F., Chronic expression of low levels of tumor necrosis factor- α in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiology of Disease 2010 37 3 630 640 2-s2.0-75949102620 10.1016/j.nbd.2009.11.018
89. Gordon R., Anantharam V., Kanthasamy A. G., Kanthasamy A., Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. Journal of Neuroinflammation 2012 9, article 82
90. Nagatsu T., Mogi M., Ichinose H., Togari A., Changes in cytokines and neurotrophins in Parkinson's disease. Journal of Neural Transmission, Supplement 2000 60 277 290 2-s2.0-0034525420 (Pubitemid 32037200)
91. Orr C. F., Rowe D. B., Halliday G. M., An inflammatory review of Parkinson's disease. Progress in Neurobiology 2002 68 5 325 340 2-s2.0-0036935553 10.1016/S0301-0082(02)00127-2 (Pubitemid 36071510)
92. Farooqui A. A., Horrocks L. A., Farooqui T., Modulation of inflammation in brain: a matter of fat. Journal of Neurochemistry 2007 101 3 577 599 2-s2.0-34247330919 10.1111/j.1471-4159.2006.04371.x (Pubitemid 46633316)
93. Benner E. J., Banerjee R., Reynolds A. D., Sherman S., Pisarev V. M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R. L., Gendelman H. E., Nitrated α -synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 2008 3 1 2-s2.0-38949151035 10.1371/journal.pone.0001376 e1376 (Pubitemid 351223140)
94. Olson J. K., Miller S. D., Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. Journal of Immunology 2004 173 6 3916 3924 2-s2.0-4644232615 (Pubitemid 39280755)
95. Miklossy J., Doudet D. D., Schwab C., Yu S., McGeer E. G., McGeer P. L., Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Experimental Neurology 2006 197 2 275 283 2-s2.0-30444443297 10.1016/j.expneurol.2005.10.034 (Pubitemid 43077135)
96. Depboylu C., Stricker S., Ghobril J. P., Oertel W. H., Priller J., Hoglinger G. U., Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Experimental Neurology 2012 238 2 183 191
97. Mosley R. L., Hutter-Saunders J. A., Stone D. K., Gendelman H. E., Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harbor Perspectives in Medicine 2012 2 1 a009381
98. Cao J., Li K., Shen Y., Activated immune cells in Parkinson's disease. Journal of Neuroimmune Pharmacology 2011 6 3 323 329 2-s2.0-79960610151 10.1007/s11481-011-9280-9
99. McGeer E. G., Singh E. A., McGeer P. L., Peripheral-type benzodiazepine binding in Alzheimer disease. Alzheimer Disease and Associated Disorders 1988 2 4 331 336 2-s2.0-0024219304
100. Petrozzi L., Lucetti C., Scarpato R., Gambaccini G., Trippi F., Bernardini S., Del Dotto P., Migliore L., Bonuccelli U., Cytogenetic alterations in lymphocytes of Alzheimer's disease and Parkinson's disease patients. Neurological Sciences 2002 23 supplement 2 S97 S98 2-s2.0-0036757504 10.1007/s100720200087 (Pubitemid 35355794)
101. Migliore L., Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Scarpato R., Trippi F., Barale R., Frenzilli G., Rodilla V., Bonuccelli U., Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 2002 58 12 1809 1815 2-s2.0-0037172827 (Pubitemid 34663582)
102. Kurkowska-Jastrzbska I., Wrońska A., Kohutnicka M., Członkowski A., Członkowska A., MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiologiae Experimentalis 1999 59 1 1 8 2-s2.0-0344076112 (Pubitemid 29100019)
103. Hisanaga K., Asagi M., Itoyama Y., Iwasaki Y., Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Archives of Neurology 2001 58 10 1580 1583 2-s2.0-0034788215 (Pubitemid 32963221)
104. Baba Y., Kuroiwa A., Uitti R. J., Wszolek Z. K., Yamada T., Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism and Related Disorders 2005 11 8 493 498 2-s2.0-27744603906 10.1016/j.parkreldis.2005.07.005 (Pubitemid 41627840)
105. + T cells are increased in patients with Parkinson's disease. Journal of the Neurological Sciences 1994 121 1 39 45 2-s2.0-0028173826 10.1016/0022-510X(94)90154-6
106. Neumann H., Wekerle H., Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. Journal of Neuropathology and Experimental Neurology 1998 57 1 1 9 2-s2.0-0031984426 (Pubitemid 28057171)
107. Gebicke-Haerter P. J., Microglia in neurodegeneration: molecular aspects. Microscopy Research and Technique 2001 54 1 47 58 2-s2.0-0035399785 10.1002/jemt.1120 (Pubitemid 32537334)
108. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH 17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 2007 13 10 1173 1175 2-s2.0-34948909646 10.1038/nm1651 (Pubitemid 47530640)
109. Kortekaas R., Leenders K. L., Van Oostrom J. C. H., Vaalburg W., Bart J., Willemsen A. T. M., Hendrikse N. H., Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology 2005 57 2 176 179 2-s2.0-13144255682 10.1002/ana.20369 (Pubitemid 40179854)
110. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
111. Haydon P. G., Carmignoto G., Astrocyte control of synaptic transmission and neurovascular coupling. Physiological Reviews 2006 86 3 1009 1031 2-s2.0-33745873475 10.1152/physrev.00049.2005 (Pubitemid 44033387)
112. Bechmann I., Galea I., Perry V. H., What is the blood-brain barrier (not)? Trends in Immunology 2007 28 1 5 11 2-s2.0-33845727067 10.1016/j.it.2006.11.007 (Pubitemid 46001619)
113. Rappold P. M., Tieu K., Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010 7 4 413 423 2-s2.0-77957048035 10.1016/j.nurt.2010.07.001
114. Nutt J. G., Wooten G. F., Diagnosis and initial management of Parkinson's disease. The New England Journal of Medicine 2005 353 10 1021 1027 2-s2.0-24344446871 10.1056/NEJMcp043908 (Pubitemid 41262336)
115. Wu D. C., Tieu K., Cohen O., Choi D., Vila M., Jackson-Lewis V., Teismann P., Przedborski S., Glial cell response: a pathogenic factor in Parkinson's disease. Journal of NeuroVirology 2002 8 6 551 558 2-s2.0-0036962803 10.1080/13550280290100905 (Pubitemid 36109117)
116. Sellers R. S., Antman M., Phillips J., Khan K. N., Furst S. M., Effects of Miglyol 812 on rats after 4 weeks of gavage as compared with methylcellulose/Tween 80. Drug and Chemical Toxicology 2005 28 4 423 432 2-s2.0-27644473439 10.1080/01480540500262839 (Pubitemid 41572101)
117. Eddelston M., Mucke L., Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience 1993 54 1 15 36 2-s2.0-0027314268 10.1016/0306-4522(93)90380-X (Pubitemid 23147085)
118. Hirsch S., Bähr M., Growth promoting and inhibitory effects of glial cells in the mammalian nervous system. Advances in Experimental Medicine and Biology 1999 468 199 205 2-s2.0-0034464972
119. Lee H., Kim C., Lee S., Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection. Oxidative Medicine and Cellular Longevity 2010 3 4 283 287 2-s2.0-77957371012 10.4161/oxim.3.4.12809
120. Sekiyama K., Sugama S., Fujita M., Sekigawa A., Takamatsu Y., Waragai M., Takenouchi T., Hashimoto M., Neuroinflammation in Parkinson's disease and related disorders: a lesson from genetically manipulated mouse models of α -synucleinopathies. Parkinson's Disease 2012 2012 8 2-s2.0-84859761962 10.1155/2012/271732 271732
121. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., Almer G., The parkinsonian toxin MPTP: action and mechanism. Restorative Neurology and Neuroscience 2000 16 2 135 142 2-s2.0-0034061442 (Pubitemid 30159159)
122. Lee H., Suk J., Patrick C., Bae E., Cho J., Rho S., Hwang D., Masliah E., Lee S., Direct transfer of α -synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. The Journal of Biological Chemistry 2010 285 12 9262 9272 2-s2.0-77950571596 10.1074/jbc.M109.081125
123. Farina C., Aloisi F., Meinl E., Astrocytes are active players in cerebral innate immunity. Trends in Immunology 2007 28 3 138 145 2-s2.0-33847099936 10.1016/j.it.2007.01.005 (Pubitemid 46283692)
124. Qureshi G. A., Baig S., Bednar I., Sodersten P., Forsberg G., Siden A., Increased cerebrospinal fluid concentration of nitrite ire Parkinson's disease. NeuroReport 1995 6 12 1642 1644 2-s2.0-0029121786
125. van der Vliet A., Eiserich J. P., Halliwell B., Cross C. E., Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite: a potential additional mechanism of nitric oxide-dependent toxicity. The Journal of Biological Chemistry 1997 272 12 7617 7625 2-s2.0-0030909465 10.1074/jbc.272.12.7617 (Pubitemid 27137309)
126. Hampton M. B., Kettle A. J., Winterbourn C. C., Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998 92 9 3007 3017 2-s2.0-0032213375 (Pubitemid 28492304)
127. Saijo K., Winner B., Carson C. T., Collier J. G., Boyer L., Rosenfeld M. G., Gage F. H., Glass C. K., A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009 137 1 47 59 2-s2.0-63049083734 10.1016/j.cell.2009.01.038
128. Klegeris A., Pelech S., Giasson B. I., Maguire J., Zhang H., McGeer E. G., McGeer P. L., α -synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiology of Aging 2008 29 5 739 752 2-s2.0-40849118624 10.1016/j.neurobiolaging.2006.11.013 (Pubitemid 351400820)
129. Ferrer I., Blanco R., Cutillas B., Ambrosio S., Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathology and Applied Neurobiology 2000 26 5 424 433 2-s2.0-0033775865 10.1046/j.1365-2990.2000.00267. x
130. Hayley S., Crocker S. J., Smith P. D., Shree T., Jackson-Lewis V., Przedborski S., Mount M., Slack R., Anisman H., Park D. S., Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. The Journal of Neuroscience 2004 24 8 2045 2053 2-s2.0-10744223673 10.1523/JNEUROSCI.4564-03.2004 (Pubitemid 38292818)
131. Karunakaran S., Saeed U., Mishra M., Valli R. K., Joshi S. D., Meka D. P., Seth P., Ravindranath V., Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. The Journal of Neuroscience 2008 28 47 12500 12509 2-s2.0-58149393845 10.1523/JNEUROSCI.4511-08.2008
132. Rus H., Cudrici C., David S., Niculescu F., The complement system in
133. Wyss-Coray T., Rogers J., Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspectives in Medicine 2012 2 1 a006346
134. McGeer P. E., Yasojima K., McGeer P. L., Inflammation in the pathogenesis of Parkinson's disease. British Columbia Medical Journal 2001 43 3 138 141
135. McGeer E. G., McGeer P. L., Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 2005 19 1 31 37 2-s2.0-15944377898 10.2165/00063030-200519010-00004 (Pubitemid 40432505)
136. Loeffler D. A., Camp D. M., Conant S. B., Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. Journal of Neuroinflammation 2006 3, article 29 2-s2.0-33750802218 10.1186/1742-2094-3-29 (Pubitemid 44712385)
137. Yamada T., McGeer E. G., Schelper R. L., Wszolek Z. K., McGeer P. L., Pfeiffer R. F., Rodnitzky R. L., Histological and biochemical pathology in a family with autosomal dominant Parkinsonism and dementia. Neurology Psychiatry and Brain Research 1993 2 1 26 35 2-s2.0-0027887313 (Pubitemid 24165725)
138. McGeer P. L., McGeer E. G., Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism and Related Disorders 2004 10 supplement 1 S3 S7 2-s2.0-1942454250 10.1016/j.parkreldis.2004.01.005 (Pubitemid 38510423)
139. Wang Y., Hancock A. M., Bradner J., Chung K. A., Quinn J. F., Peskind E. R., Galasko D., Jankovic J., Zabetian C. P., Kim H. M., Leverenz J. B., Montine T. J., Ginghina C., Edwards K. L., Snapinn K. W., Goldstein D. S., Shi M., Zhang J., Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. American Journal of Pathology 2011 178 4 1509 1516 2-s2.0-79953667345 10.1016/j.ajpath.2011.01.006
140. Bonifati D. M., Kishore U., Role of complement in neurodegeneration and neuroinflammation. Molecular Immunology 2007 44 5 999 1010 2-s2.0-33748780095 10.1016/j.molimm.2006.03.007 (Pubitemid 44414994)
141. Ricklin D., Hajishengallis G., Yang K., Lambris J. D., Complement: a key system for immune surveillance and homeostasis. Nature Immunology 2010 11 9 785 797 2-s2.0-77955883153 10.1038/ni.1923
142. van Beek J., Elward K., Gasque P., Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Annals of the New York Academy of Sciences 2003 992 56 71 2-s2.0-0037791771 (Pubitemid 36706637)
143. Shen Y., Meri S., Yin and Yang: complement activation and regulation in Alzheimer's disease. Progress in Neurobiology 2003 70 6 463 472 2-s2.0-0141991166 10.1016/j.pneurobio.2003.08.001 (Pubitemid 37249427)
144. O'Barr S., Cooper N. R., The C5a complement activation peptide increases IL-1 β and IL-6 release from amyloid- β primed human monocytes: implications for Alzheimer's disease. Journal of Neuroimmunology 2000 109 2 87 94 2-s2.0-0034703179 10.1016/S0165-5728(00)00291-5
145. Depboylu C., Schäfer M. K.-H., Arias-Carrión O., Oertel W. H., Weihe E., Höglinger G. U., Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. Journal of Neuropathology and Experimental Neurology 2011 70 2 125 132 2-s2.0-79251600760 10.1097/NEN.0b013e31820805b9
146. Lee H., Choi J., Suk K., Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. Movement Disorders 2011 26 13 2364 2370 2-s2.0-81955160674 10.1002/mds.23871
147. Yin G. N., Lee H. W., Cho J., Suk K., Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Research 2009 1265 158 170 2-s2.0-62949121626 10.1016/j.brainres.2009.01. 058